Monday May 29th 2017

[Comment] Trial and error in clinical studies: lessons from ATAMS

Multiple sclerosis is one of the most prevalent neurological diseases in young adults and causes progressive and permanent disability in about a third of patients. Thus a treatment that halts or, even better, reverses disease progression is desperately needed, but unfortunately is not on the horizon. Nevertheless, substantial progress has been made in research into the treatment of multiple sclerosis during the past 20 years. The consensus is that at least the majority of multiple sclerosis cases have an autoimmune pathogenesis, so existing treatment protocols focus mainly on immune modulation. (Source: Lancet Neurology)

Read this article: 

[Comment] Trial and error in clinical studies: lessons from ATAMS

Leave a Comment

More from category

Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis
Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis

An expert panel is tackling the first revision to the multiple sclerosis diagnostic criteria in 7 years. Among proposed [Read More]

Connecticut State Budget Call to Action
Connecticut State Budget Call to Action

/About-the-Society/News/Connecticut-State-Budget-Call-to-Action [Read More]

A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis
A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis

Medscape sits down with two neurologists to discuss advances in multiple sclerosis as presented at this year's American [Read More]

Progress on Bills to Address Step Therapy
Progress on Bills to Address Step Therapy

/About-the-Society/News/Progress-on-Bills-to-Address-Step-Therapy [Read More]

Brain Gadolinium Deposition Varies With Contrast Agent in MS Brain Gadolinium Deposition Varies With Contrast Agent in MS
Brain Gadolinium Deposition Varies With Contrast Agent in MS Brain Gadolinium Deposition Varies With Contrast Agent in MS

Gadolinium accumulation in the brain is greater with linear GBCAs than with macrocyclics. Multiple sclerosis experts [Read More]